65th ASH Annual Meeting & Exposition: Janssen invites you to learn about a treatment for adult patients with RRMM who have received at least four prior lines of therapy, including a PI, IMiD, and anti-CD38 monoclonal antibody

-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member

denotes an abstract that is clinically relevant.

denotes that this is a recommended PHD Trainee Session.

denotes that this is a ticketed session.

Janssen invites you to learn about a treatment for adult patients with RRMM who have received at least four prior lines of therapy, including a PI, IMiD, and anti-CD38 monoclonal antibody

Sponsor: Johnson & Johnson

Product Theaters

Room 1B (San Diego Convention Center)

Speaker:

Agne Paner-Straseviciute, MD, Johnson & Johnson

Disclosures:

No relevant conflicts of interest to declare.

For In-Person Participants Only

See more of: Product Theaters